IA
ITCI

IFP Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

IFP Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,440
Closed -$586K – 5053
2025
Q1 		$586K Sell
4,440
-337
-7% -$42K 0.02% 723
2024
Q4 		$399K Buy
4,777
+2,348
+97% +$193K 0.01% 821
2024
Q3 		$178K Buy
+2,429
New +$183K 0.01% 1144
2024
Q2 		– Sell
-17
Closed -$1.18K – 3364
2024
Q1 		$1.18K Buy
+17
New +$1.17K ﹤0.01% 2828
2023
Q3 		– Sell
-19
Closed -$1.2K – 3586
2023
Q2 		$1.2K Buy
+19
New +$1.18K ﹤0.01% 3033
2022
Q4 		– Sell
-401
Closed -$10K – 4876
2022
Q3 		$10K Sell
401
-200
-33% -$10.4K ﹤0.01% 3679
2022
Q2 		$15K Hold
601
– – ﹤0.01% 3114
2022
Q1 		$15K Buy
+601
New +$31.2K ﹤0.01% 3114
2017
Q3 		– Sell
-300
Closed -$4K – 4238
2017
Q2 		$4K Hold
300
– – ﹤0.01% 3549
2017
Q1 		$5K Hold
300
– – ﹤0.01% 3339
2016
Q4 		$5K Hold
300
– – ﹤0.01% 3335
2016
Q3 		$5K Sell
300
-200
-40% -$8.09K ﹤0.01% 3264
2016
Q2 		$19K Buy
+500
New +$18K ﹤0.01% 2388

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

IFP Advisors's ITCI Position: Q2 2025 in Review

IFP Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,440 shares — an estimated $586K sold.

IFP Advisors first reported a position in ITCI in Q2 2016 and held it in 13 quarters. The position peaked at $586K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • IFP Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • IFP Advisors sold 4,440 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $586K.
  • IFP Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 13 quarters.
  • IFP Advisors's Intra-Cellular Therapies Inc. position peaked at $586K in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.